Evidentic • Therapeutic Indications • Colorectal cancer
Colorectal cancer is a type of cancer that occurs in the colon or rectum. Sometimes abnormal growths, called polyps, appear in the colon or rectum. Over time, some polyps may develop into cancer. Screening tests can find polyps so they can be removed before they become cancer.
Showing all 11 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price | |
---|---|---|---|---|---|---|---|---|---|---|
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
2 mg |
-80°C |
11/2019 |
224,00Â € |
||
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
2 mg |
-80°C |
01/2020 |
224,00Â € |
||
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
2 mg |
-80°C |
05/2021 |
224,00Â € |
||
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
5 mg |
-80°C |
09/2021 |
561,00Â € |
||
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
2 mg |
-80°C |
11/2021 |
224,00Â € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
03/2018 |
234,00Â € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
06/2018 |
234,00Â € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
08/2018 |
234,00Â € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
01/2019 |
234,00Â € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
234,00Â € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
06/2020 |
234,00Â € |
Let us know about your inquiry details and we’ll contact you shortly.